{
    "id": 352,
    "fullName": "EGFR amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "EGFR amp indicates an increased number of copies of the EGFR gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "amp",
    "createDate": "03/13/2014",
    "updateDate": "07/30/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5941,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, three urothelial carcinoma patients with EGFR amplification in the absence of other ERBB family member alterations, received no benefit from Gilotrif (afatinib) therapy (PMID: 27044931).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5203,
                    "pubMedId": 27044931,
                    "title": "Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27044931"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14014,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, anti-Egfr antibody therapies including Erbitux (cetuximab) and ABT-806, alone or in combination with chemotherapy, resulted in an objective response in 57% (4/7, 3 complete response, 1 partial response), and disease control in 43% (3/7) of patients with EGFR amplified gastric and esophagogastric junction adenocarcinoma with a mean circulating tumor DNA copy number of 2.5 in non-responders vs 33.9 in responders (p=0.049) (PMID: 29449271).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 4256,
                "therapyName": "ABT-806",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11409,
                    "pubMedId": 29449271,
                    "title": "Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29449271"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2553,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MM-151 antagonized EGFR activity and inhibited proliferation in several tumor cell lines in culture (PMID: 25911688).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 821,
                "therapyName": "MM-151",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3282,
                    "pubMedId": 25911688,
                    "title": "Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25911688"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14015,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, anti-Egfr antibody therapies including Erbitux (cetuximab) and ABT-806, alone or in combination with chemotherapy, resulted in an objective response in 57% (4/7, 3 complete response, 1 partial response), and disease control in 43% (3/7) of patients with EGFR amplified gastric and esophagogastric junction adenocarcinoma with a mean circulating tumor DNA copy number of 2.5 in non-responders vs 33.9 in responders (p=0.049) (PMID: 29449271).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 4256,
                "therapyName": "ABT-806",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11409,
                    "pubMedId": 29449271,
                    "title": "Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29449271"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7897,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Erbitux (cetuximab) in a cell viability assay (PMID: 27207775).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7776,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of two unspecified EGFR antibodies targeting nonoverlapping epitopes of Egfr resulted in Egfr degradation and inhibition of proliferation in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 4575,
                "therapyName": "unspecified EGFR antibody",
                "synonyms": null
            },
            "indication": {
                "id": 11934,
                "name": "head and neck cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6493,
                    "pubMedId": 27196767,
                    "title": "Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196767"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7896,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Erbitux (cetuximab) in a cell viability assay (PMID: 27207775).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14013,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, anti-Egfr antibody therapies including Erbitux (cetuximab) and ABT-806, alone or in combination with chemotherapy, resulted in an objective response in 57% (4/7, 3 complete response, 1 partial response), and disease control in 43% (3/7) of patients with EGFR amplified gastric and esophagogastric junction adenocarcinoma with a mean circulating tumor DNA copy number of 2.5 in non-responders vs 33.9 in responders (p=0.049) (PMID: 29449271).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11409,
                    "pubMedId": 29449271,
                    "title": "Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29449271"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14012,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, anti-Egfr antibody therapies including Erbitux (cetuximab) and ABT-806, alone or in combination with chemotherapy, resulted in an objective response in 57% (4/7, 3 complete response, 1 partial response), and disease control in 43% (3/7) of patients with EGFR amplified gastric and esophagogastric junction adenocarcinoma with a mean circulating tumor DNA copy number of 2.5 in non-responders vs 33.9 in responders (p=0.049) (PMID: 29449271).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11409,
                    "pubMedId": 29449271,
                    "title": "Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29449271"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7514,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SHP099 inhibited ERK activation and reduced proliferation of an EGFR-amplified triple-negative breast cancer cell line in culture (PMID: 27362227).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6394,
                    "pubMedId": 27362227,
                    "title": "Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27362227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8230,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ganetespib inhibited growth of a non-small cell lung cancer cell line with EGFR amplification and overexpression in culture (PMID: 25077897).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 745,
                "therapyName": "Ganetespib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2971,
                    "pubMedId": 25077897,
                    "title": "The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25077897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7898,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Tarceva (erlotinib) in a cell viability assay (PMID: 27207775).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 847,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II clinical trial, Torisel (temsirolimus) in combination with Tarceva (erlotinib) demostrated minimal efficacy at the maximum tolerated dosage in high-grade glioma patients, with no correlation between EGFR amplification and survival (PMID: 24470557).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 1340,
                "therapyName": "Erlotinib + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 491,
                    "pubMedId": 24470557,
                    "title": "Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24470557"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10100,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Iressa (gefitinib) and PF-573228 resulted in a synergistic effect in a triple-receptor negative breast cancer cell line harboring EGFR amplification, demonstrating decreased colony formation in culture (PMID: 27793840).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 5389,
                "therapyName": "Gefitinib + PF-573228",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8020,
                    "pubMedId": 27793840,
                    "title": "Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27793840"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7780,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Igf-1r antibody resulted in growth inhibition in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 4578,
                "therapyName": "unspecified EGFR antibody + unspecified IGF-1R antibody",
                "synonyms": null
            },
            "indication": {
                "id": 11934,
                "name": "head and neck cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6493,
                    "pubMedId": 27196767,
                    "title": "Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196767"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7894,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Tarceva (erlotinib) in a cell viability assay (PMID: 27207775).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6933,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-414 demonstrated cytoxicity against an EGFR-amplified head and neck squamous cell carcinoma (HNSCC) cell line in culture and induced tumor regression in EGFR-amplified HNSCC cell line xenograft models (PMID: 26846818).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5960,
                    "pubMedId": 26846818,
                    "title": "ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26846818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 140,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, Erbitux (cetuximab) promoted tumor growth inhibition in several patient-derived xenograft models of gastric cancers with EGFR amplification (PMID: 24141978).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 3119,
                "name": "gastrointestinal system cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 973,
                    "pubMedId": 24141978,
                    "title": "A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24141978"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6996,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-414 demonstrated cytotoxicity against a EGFR-amplified triple-negative breast cancer cell line in culture (PMID: 26846818).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5960,
                    "pubMedId": 26846818,
                    "title": "ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26846818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14474,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Depatuxizumab mafodotin (ABT-414) treatment resulted in partial response in a patient with EGFR amplified triple-receptor negative breast cancer (PMID: 29533458; NCT01741727).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11643,
                    "pubMedId": 29533458,
                    "title": "Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533458"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3741,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ABT-414 displayed safety and preliminary efficacy in advanced solid tumor patients with EGFR amplification (J Clin Oncol 33, 2015 (suppl; abstr 2510)).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4090,
                    "pubMedId": null,
                    "title": "ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR)",
                    "url": "http://meetinglibrary.asco.org/content/146940-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14472,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Depatuxizumab mafodotin (ABT-414) treatment resulted in partial response in 1.8% (1/56) and stable disease in 23% (13/56) of patients with advanced solid tumor harboring EGFR amplification, overexpression, or mutated EGFR variant III (PMID: 29533458; NCT01741727).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11643,
                    "pubMedId": 29533458,
                    "title": "Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533458"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13977,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ZODIAC), Caprelsa (vandetanib) and Taxotere (docetaxel) combination treatment resulted in improved progression-free survival (HR=0.61), overall survival (HR=0.48), and objective response (odd ratio=3.90) in non-small cell lung cancer patients harboring EGFR amplification compared to the overall study population (PMID: 25057173; NCT00312377).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 2935,
                "therapyName": "Docetaxel + Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3279,
                    "pubMedId": 25057173,
                    "title": "EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25057173"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3239,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Caprelsa (vandetinib), in combination with radiation therapy and Temodar (temozolomide), demonstrated no difference in PFS and OS in glioblastoma patients harboring EGFR amplification versus glioblastoma patients without EGFR amplification (PMID: 25910950).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 3094,
                "therapyName": "Temozolomide + Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3688,
                    "pubMedId": 25910950,
                    "title": "A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25910950"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10109,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tarceva (erlotinib) and PF-431396 resulted in a synergistic effect in a triple-receptor negative breast cancer cell line harboring EGFR amplification, demonstrating inhibition of cell growth in culture (PMID: 27793840).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 5393,
                "therapyName": "Erlotinib + PF-431396",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8020,
                    "pubMedId": 27793840,
                    "title": "Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27793840"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2554,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III study, response to Vectibix (pantitumumab) was associated with EGFR amplification in colorectal cancer patients (PMID: 17664472).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3284,
                    "pubMedId": 17664472,
                    "title": "Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17664472"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9358,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with Depatuxizumab mafodotin (ABT-414) resulted in an overall response rate of 6.7% (3/59; 1 complete response and 2 partial responses), stable disease in 41% (27/66), and a progression-free survival rate of 28.8% (95% CI 18.5, 39.9%) at 6 months in patients with EGFR-amplified recurrent glioblastoma (PMID: 29075855; NCT01800695).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7123,
                    "pubMedId": null,
                    "title": "EFFICACY OF A NOVEL ANTIBODY-DRUG CONJUGATE (ADC), ABT-414, AS MONOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (EGFRamp), RECURRENT GLIOBLASTOMA (rGBM)",
                    "url": "http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi2.3.abstract?sid=ef6007c0-0537-40d1-920d-fceb55d555f5"
                },
                {
                    "id": 10363,
                    "pubMedId": 29075855,
                    "title": "Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29075855"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6072,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited growth of head and neck squamous cell carcinoma (HNSCC) cell lines in culture, and inhibited tumor growth in HNSCC cell line xenograft models, with highest efficacy against EGFR-amplified cell lines (PMID: 25559287).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2348,
                    "pubMedId": 25559287,
                    "title": "Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25559287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7779,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Erbb3 (Her3) antibody resulted in inhibition of survival in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 4579,
                "therapyName": "unspecified EGFR antibody + unspecified ERBB3 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 11934,
                "name": "head and neck cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6493,
                    "pubMedId": 27196767,
                    "title": "Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196767"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6891,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ABT-806 treatment resulted in stable disease for more than 2.5 years in a penile cancer patient harboring EGFR amplification (PMID: 25895099).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 4256,
                "therapyName": "ABT-806",
                "synonyms": null
            },
            "indication": {
                "id": 11615,
                "name": "penile cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5781,
                    "pubMedId": 25895099,
                    "title": "A phase 1 study of ABT-806 in subjects with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25895099"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8043,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) inhibited Egfr signaling and survival of patient-derived EGFR amplified glioblastoma cells in culture and in intracranial xenograft models (PMID: 25939761).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6540,
                    "pubMedId": 25939761,
                    "title": "Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939761"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7513,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SHP099 inhibited ERK activation and reduced proliferation of EGFR-amplified esophageal squamous cell carcinoma cells in culture, and inhibited tumor growth in EGFR-amplified esophageal squamous cell carcinoma cell line xenograft models (PMID: 27362227).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6394,
                    "pubMedId": 27362227,
                    "title": "Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27362227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7781,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of an unspecified EGFR antibody, an unspecified Erbb3 (Her3) antibody, and an unspecified Igf-1r antibody resulted in potent inhibition of survival in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 4580,
                "therapyName": "unspecified EGFR antibody + unspecified ERBB3 antibody + unspecified IGF-1R antibody",
                "synonyms": null
            },
            "indication": {
                "id": 11934,
                "name": "head and neck cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6493,
                    "pubMedId": 27196767,
                    "title": "Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196767"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4101,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with esophageal adenocarcinoma progressed on AMG 337 therapy upon outgrowth of EGFR amplified tumor cells (PMID: 26432108).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 4914,
                "name": "esophagus adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4397,
                    "pubMedId": 26432108,
                    "title": "Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7892,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Gilotrif (afatinib) in a cell viability assay (PMID: 27207775).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10104,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Iressa (gefitinib) and PF-431396 resulted in a synergistic effect in a triple-receptor negative breast cancer cell line harboring EGFR amplification, demonstrating a decrease in colony formation in culture (PMID: 27793840).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 5391,
                "therapyName": "Gefitinib + PF-431396",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8020,
                    "pubMedId": 27793840,
                    "title": "Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27793840"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1860,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) and Iressa (gefitinib) acted synergistically to decrease downstream signaling activity and inhibit cell growth of glioblastoma cell lines with EGFR and PDGFRA coamplification (PMID: 22323597).",
            "molecularProfile": {
                "id": 4004,
                "profileName": "EGFR amp PDGFRA amp"
            },
            "therapy": {
                "id": 2483,
                "therapyName": "Gefitinib + Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2352,
                    "pubMedId": 22323597,
                    "title": "Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22323597"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3219,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a colorectal cancer patient harboring both EGFR amplification and EGFR S492R demonstrated a greater than 50% reduction in liver lesion volume when treated with Vectibix (panitumumab) (PMID: 22270724).",
            "molecularProfile": {
                "id": 12767,
                "profileName": "EGFR S492R EGFR amp"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3682,
                    "pubMedId": 22270724,
                    "title": "Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22270724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3220,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, EGFR S492R was detected in a colorectal cancer patient harboring EGFR amplification who progressed on an Erbitux (cetuximab) containing regimen, and resistance to Erbitux (cetuximab) was supported by lack of growth inhibition in colorectal cancer cells harboring EGFR S492R and EGFR amplification in culture (PMID: 22270724).",
            "molecularProfile": {
                "id": 12767,
                "profileName": "EGFR S492R EGFR amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3682,
                    "pubMedId": 22270724,
                    "title": "Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22270724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3221,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, EGFR S492R was detected in the post-Erbitux (cetuximab) sample from a colorectal cancer patient harboring EGFR amplification and BRAF V600E who progressed on an Erbitux (cetuximab) regimen (PMID: 22270724).",
            "molecularProfile": {
                "id": 12768,
                "profileName": "BRAF V600E EGFR S492R EGFR amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3682,
                    "pubMedId": 22270724,
                    "title": "Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22270724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15167,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, two patients with non-small cell lung cancer harboring EGFR amplification and EGFR T790M progressed after Tagrisso (osimertinib) treatment, and were found to have lost the EGFR T790M and acquired MET amplification (PMID: 30268451).",
            "molecularProfile": {
                "id": 17304,
                "profileName": "EGFR amp MET amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12768,
                    "pubMedId": 30268451,
                    "title": "Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30268451"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15165,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung cancer harboring EGFR amplification progressed after Iressa (gefitinib) treatment, and was found to have acquired MET amplification (PMID: 30268451).",
            "molecularProfile": {
                "id": 17304,
                "profileName": "EGFR amp MET amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12768,
                    "pubMedId": 30268451,
                    "title": "Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30268451"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15168,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung cancer harboring EGFR amplification progressed after Tarceva (erlotinib) treatment, and was found to have acquired a MET amplification (PMID: 30268451).",
            "molecularProfile": {
                "id": 17304,
                "profileName": "EGFR amp MET amp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12768,
                    "pubMedId": 30268451,
                    "title": "Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30268451"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11557,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with EGFR and MET copy number gain in culture (PMID: 27595477).",
            "molecularProfile": {
                "id": 17304,
                "profileName": "EGFR amp MET amp"
            },
            "therapy": {
                "id": 3440,
                "therapyName": "Crizotinib + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4914,
                "name": "esophagus adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9641,
                    "pubMedId": 27595477,
                    "title": "Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27595477"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16677,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a gastric cancer patient with co-amplification of EGFR and ERBB2 (HER2) who previously progressed on a combination therapy with Herceptin (trastuzumab) demonstrated a 37% tumor regression when treated with Gilotrif (afatinib) (PMID: 30463996; NCT01522768).",
            "molecularProfile": {
                "id": 22032,
                "profileName": "EGFR amp ERBB2 amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14704,
                    "pubMedId": 30463996,
                    "title": "EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30463996"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5942,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, two urothelial carcinoma patients with ERBB2 (HER2) and EGFR co-amplification had improved progression free survival when treated with Gilotrif (afatinib), and median PFS was 6.6 months for patients with ERBB2 or ERBB3 alterations relative to 1.4 months for patients lacking alterations (PMID: 27044931).",
            "molecularProfile": {
                "id": 22032,
                "profileName": "EGFR amp ERBB2 amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5203,
                    "pubMedId": 27044931,
                    "title": "Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27044931"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16679,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a metastatic gastric adenocarcinoma patient with co-amplification of EGFR and ERBB2 (HER2) demonstrated a 43% tumor regression by RECIST when treated with Gilotrif (afatinib) (PMID: 30463996; NCT01522768).",
            "molecularProfile": {
                "id": 22032,
                "profileName": "EGFR amp ERBB2 amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14704,
                    "pubMedId": 30463996,
                    "title": "EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30463996"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16678,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase II clinical trial, a patient with metastatic gastric adenocarcinoma progressed while on the combination therapy of Adrucil (fluorouracil), Eloxatin (oxaliplatin), and Herceptin (trastuzumab), and was subsequently found to have acquired co-amplification of EGFR and ERBB2 (HER2) in the liver metastasis (PMID: 30463996; NCT01522768).",
            "molecularProfile": {
                "id": 22032,
                "profileName": "EGFR amp ERBB2 amp"
            },
            "therapy": {
                "id": 8124,
                "therapyName": "Fluorouracil + Oxaliplatin + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14704,
                    "pubMedId": 30463996,
                    "title": "EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30463996"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16662,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, co-amplification of EGFR and ERBB2 (HER2) was identified at the time of progression in a patient with ERBB2 (HER2)-positive gastric cancer who initially demonstrated a short response to the combination therapy of Herceptin (trastuzumab), Adrucil (fluorouracil), and Eloxatin (oxaliplatin), but then progression at 7 months (PMID: 30463996; NCT01522768).",
            "molecularProfile": {
                "id": 22032,
                "profileName": "EGFR amp ERBB2 amp"
            },
            "therapy": {
                "id": 8124,
                "therapyName": "Fluorouracil + Oxaliplatin + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14704,
                    "pubMedId": 30463996,
                    "title": "EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30463996"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5945,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a urothelial carcinoma patient with EGFR and ERBB2 (HER2) co-amplificaction and an ERBB3 R103G mutation never progressed while being treated with Gilotrif (afatinib) (PMID: 27044931).",
            "molecularProfile": {
                "id": 22034,
                "profileName": "EGFR amp ERBB2 amp ERBB3 R103G"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5203,
                    "pubMedId": 27044931,
                    "title": "Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27044931"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6037,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22287,
                "profileName": "EGFR act mut EGFR amp PTEN R308C"
            },
            "therapy": {
                "id": 4008,
                "therapyName": "Gefitinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6045,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22287,
                "profileName": "EGFR act mut EGFR amp PTEN R308C"
            },
            "therapy": {
                "id": 4009,
                "therapyName": "BMS-754807 + Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6040,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification and EGFR G719A in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22289,
                "profileName": "EGFR G719A EGFR amp"
            },
            "therapy": {
                "id": 4008,
                "therapyName": "Gefitinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6044,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification and EGFR G719A in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22289,
                "profileName": "EGFR G719A EGFR amp"
            },
            "therapy": {
                "id": 4009,
                "therapyName": "BMS-754807 + Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6048,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) inhibited survival of InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6050,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII were resistant to Linsitinib (OSI-906)-induced growth inhibition in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 798,
                "therapyName": "Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6049,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) inhibited survival of InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6053,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 combination treatment did not improve growth inhibition compared to single therapy in InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 4009,
                "therapyName": "BMS-754807 + Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6051,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII were resistant to BMS-754807-induced growth inhibition in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 686,
                "therapyName": "BMS-754807",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6052,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) combination treatment did not improve growth inhibition compared to single therapy in InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 4008,
                "therapyName": "Gefitinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6932,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-414 demonstrated cytotoxicity against a lung adenocarcinoma cell line that harbored EGFR amplification and EGFR E746_A750del in culture and induced tumor regression in cell line xenograft models (PMID: 26846818).",
            "molecularProfile": {
                "id": 24031,
                "profileName": "EGFR E746_A750del EGFR amp"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5960,
                    "pubMedId": 26846818,
                    "title": "ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26846818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6994,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-414 in combination with Temodar (temozolomide) and radiotherapy inhibited tumor growth and resulted in tumor growth delay in a glioblastoma multiforme cell line xenograft model harboring amplified EGFR vIII (exon 2-7 deletion), with increased efficacy compared to the combination of Temodar (temozolomide) and radiotherapy (PMID: 26846818).",
            "molecularProfile": {
                "id": 24170,
                "profileName": "EGFR act mut EGFR amp"
            },
            "therapy": {
                "id": 4346,
                "therapyName": "Depatuxizumab mafodotin + Radiotherapy + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5960,
                    "pubMedId": 26846818,
                    "title": "ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26846818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6981,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-414 induced cytoxicity in a glioblastoma cell line harboring amplified EGFR vIII (exon 2-7 deletion) in culture, and induced complete tumor regression in cell line xenograft models of glioblastoma harboring amplified EGFR vIII (PMID: 26846818).",
            "molecularProfile": {
                "id": 24170,
                "profileName": "EGFR act mut EGFR amp"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5960,
                    "pubMedId": 26846818,
                    "title": "ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26846818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6991,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-414 induced tumor regression in a patient-derived xenograft model of glioblastoma multiforme harboring amplified wild-type EGFR and EGFR vIII (exon 2-7 deletion) (PMID: 26846818).",
            "molecularProfile": {
                "id": 24172,
                "profileName": "EGFR act mut EGFR amp EGFR wild-type"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5960,
                    "pubMedId": 26846818,
                    "title": "ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26846818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7637,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Selumetinib (AZD6244) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7666,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 4542,
                "therapyName": "Cetuximab + Dabrafenib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7663,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7665,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7634,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Selumetinib (AZD6244), and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 4540,
                "therapyName": "Cetuximab + Selumetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7633,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 4536,
                "therapyName": "Cetuximab + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7635,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7636,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7621,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired EGFR amplification (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 3773,
                "therapyName": "Selumetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7632,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7664,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25921,
                "profileName": "BRAF V600E EGFR amp"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8045,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived EGFR amplified glioblastoma cells harboring PTEN loss demonstrated reduced sensitivity to Vizimpro (dacomitinib) induced growth inhibition in culture and in xenograft models (PMID: 25939761).",
            "molecularProfile": {
                "id": 26141,
                "profileName": "EGFR amp PTEN loss"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6540,
                    "pubMedId": 25939761,
                    "title": "Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939761"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10107,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of PTK2B in a triple-receptor negative breast cancer xenograft model harboring EGFR amplification enhanced treatment with Iressa (gefitinib), resulting in reduced tumor size and near complete tumor remission in some of the models (PMID: 27793840).",
            "molecularProfile": {
                "id": 27254,
                "profileName": "EGFR amp PTK2B dec exp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8020,
                    "pubMedId": 27793840,
                    "title": "Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27793840"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11184,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cell lines with co-amplification of FGFR1 and EGFR demonstrated insensitivity to Balversa (erdafitinib) in culture (PMID: 28341788).",
            "molecularProfile": {
                "id": 27922,
                "profileName": "EGFR amp FGFR1 amp"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9140,
                    "pubMedId": 28341788,
                    "title": "Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28341788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11185,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and EGFR and harboring KRAS G13C demonstrated insensitivity to Balversa (erdafitinib) in culture (PMID: 28341788).",
            "molecularProfile": {
                "id": 27923,
                "profileName": "EGFR amp FGFR1 amp KRAS G13C"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9140,
                    "pubMedId": 28341788,
                    "title": "Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28341788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13059,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Theliatinib treatment resulted in tumor regression in patient-derived xenograft (PDX) models of esophageal cancer with both EGFR amplification and Egfr overexpression (PMID: 28881608)",
            "molecularProfile": {
                "id": 28988,
                "profileName": "EGFR amp EGFR over exp"
            },
            "therapy": {
                "id": 3668,
                "therapyName": "Theliatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10940,
                    "pubMedId": 28881608,
                    "title": "Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28881608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13081,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified EGFR amplification in 2 patients demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).",
            "molecularProfile": {
                "id": 28997,
                "profileName": "EGFR amp ERBB2 over exp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10846,
                    "pubMedId": 29208673,
                    "title": "Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29208673"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4642,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR G696_P1033dup had a partial response after two cycles of Gilotrif (afatinib), but subsequently developed resistance to the therapy after amplification of EGFR (PMID: 26286086).",
            "molecularProfile": {
                "id": 29854,
                "profileName": "EGFR G696_P1033dup EGFR amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4643,
                    "pubMedId": 26286086,
                    "title": "EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26286086"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14610,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, EGFR amplification (PMID: 29636358).",
            "molecularProfile": {
                "id": 30339,
                "profileName": "EML4 - ALK EGFR amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11739,
                    "pubMedId": 29636358,
                    "title": "Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29636358"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15503,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, two patients with non-small cell lung carcinoma each harboring a MET exon 14 splice site mutation initially responded to treatment with Xalkori (crizotinib), however, each patient developed resistance after 14 months and 2 months, and both were found to harbor amplification of KRAS and EGFR (PMID: 30072474).",
            "molecularProfile": {
                "id": 31072,
                "profileName": "EGFR amp KRAS amp MET del exon14"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13406,
                    "pubMedId": 30072474,
                    "title": "Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30072474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15701,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acquired resistance to Rociletinib (CO-1686) treatment in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture was associated with EGFR amplification and reduced expression of EGFR E746_A750del and EGFR T790M, and proliferation and EGFR pathway signaling were maintained upon Rociletinib (CO-1686) treatment in culture (PMID: 30322949).",
            "molecularProfile": {
                "id": 31154,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR amp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13578,
                    "pubMedId": 30322949,
                    "title": "KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322949"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15699,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a Rociletinib (CO-1686)-resistant non-small cell lung cancer cell line harboring EGFR E746_A750del and EGFR T790M with EGFR amplification, which demonstrated reduced expression of EGFR E746_A750del and EGFR T790M relative to the parental cell line, exhibited reduced proliferation and increased apoptosis in response to combined Gilotrif (afatinib) and Erbitux (cetuximab) treatment relative to Gilotrif (afatinib) alone in culture (PMID: 30322949).",
            "molecularProfile": {
                "id": 31154,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR amp"
            },
            "therapy": {
                "id": 4190,
                "therapyName": "Afatinib + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13578,
                    "pubMedId": 30322949,
                    "title": "KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322949"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15821,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase I and a Phase II trial, EGFR amplification was identified at disease progression in 9% (4/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, 70%; L858R, 28%) treated with Rociletinib (CO-1686), conversely, preexisting MET, ERBB2 (HER2), or EGFR amplification were more common in patients with primary resistance to Rociletinib (CO-1686) (PMID: 27283993; NCT01526928, NCT02147990).",
            "molecularProfile": {
                "id": 31243,
                "profileName": "EGFR T790M EGFR act mut EGFR amp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16680,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a metastatic gastric adenocarcinoma patient with co-amplification of EGFR and ERBB2 (HER2) who initially responded to Gilotrif (afatinib) treatment progressed at 12 weeks and was found to have acquired amplification of MET in the progressing sites, which was subsequently confirmed to be associated with resistance via a patient-derived xenograft (PDX) model treated with Gilotrif (afatinib) (PMID: 30463996; NCT01522768).",
            "molecularProfile": {
                "id": 31753,
                "profileName": "EGFR amp ERBB2 amp MET amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14704,
                    "pubMedId": 30463996,
                    "title": "EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30463996"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16681,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a gastric adenocarcinoma patient-derived xenograft (PDX) model with amplification of EGFR, ERBB2 (HER2), and MET demonstrated resistance to treatment with AMG 337 (PMID: 30463996; NCT01522768).",
            "molecularProfile": {
                "id": 31753,
                "profileName": "EGFR amp ERBB2 amp MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14704,
                    "pubMedId": 30463996,
                    "title": "EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30463996"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16682,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, preclinical analysis of a gastric adenocarcinoma patient-derived xenograft (PDX) model with amplification of EGFR, ERBB2 (HER2), and MET demonstrated tumor regression when treated with a combination of Gilotrif (afatinib) and AMG 337 (PMID: 30463996; NCT01522768).",
            "molecularProfile": {
                "id": 31753,
                "profileName": "EGFR amp ERBB2 amp MET amp"
            },
            "therapy": {
                "id": 8125,
                "therapyName": "Afatinib + AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14704,
                    "pubMedId": 30463996,
                    "title": "EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30463996"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18046,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, EGFR amplification was identified as a potential acquired resistance mechanism in 23% (7/30) of patients with non-small cell lung cancer harboring EGFR T790M whose disease progressed while on Abivertinib (AC0010) treatment (PMID: 31027916; NCT02330367).",
            "molecularProfile": {
                "id": 32952,
                "profileName": "EGFR T790M EGFR amp"
            },
            "therapy": {
                "id": 2909,
                "therapyName": "Abivertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15973,
                    "pubMedId": 31027916,
                    "title": "Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31027916"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19044,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tarceva (erlotinib) treatment resulted in a partial response lasted for 7 months in a patient with metastatic lung adenocarcinoma harboring EGFR amplification and EGFR I744_K745delinsKIPVAI (PMID: 21841502).",
            "molecularProfile": {
                "id": 33828,
                "profileName": "EGFR I744_K745delinsKIPVAI EGFR amp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16690,
                    "pubMedId": 21841502,
                    "title": "Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21841502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20335,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with non-small cell lung cancer harboring MET D1010H and EGFR amplification demonstrated a best objective response of stable disease for 21.2 months when treated with Glesatinib (MGCD265) (PMID: 32034073).",
            "molecularProfile": {
                "id": 35122,
                "profileName": "EGFR amp MET D1010H"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17807,
                    "pubMedId": 32034073,
                    "title": "Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32034073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20339,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with non-small cell lung cancer harboring MET D1010H treated with Capmatinib (INC280) demonstrated resistance and was found via tissue testing to have acquired EGFR amplification and ERBB3 (HER3) amplification and via plasma testing to have acquired MET D1228N (PMID: 32034073).",
            "molecularProfile": {
                "id": 35131,
                "profileName": "EGFR amp ERBB3 amp MET D1010H MET D1228N"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17807,
                    "pubMedId": 32034073,
                    "title": "Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32034073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21307,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) decreased EGFR phosphorylation levels and inhibited growth of lung adenocarcinoma cells harboring EGFR exon 19 deletion and EGFR amplification in culture (PMID: 32130260).",
            "molecularProfile": {
                "id": 36194,
                "profileName": "EGFR exon 19 del EGFR amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18612,
                    "pubMedId": 32130260,
                    "title": "Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32130260"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21308,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) decreased EGFR phosphorylation levels and inhibited growth of lung adenocarcinoma cells harboring EGFR exon 19 deletion and EGFR amplification in culture (PMID: 32130260).",
            "molecularProfile": {
                "id": 36194,
                "profileName": "EGFR exon 19 del EGFR amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18612,
                    "pubMedId": 32130260,
                    "title": "Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32130260"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 447,
            "profileName": "EGFR amp",
            "profileTreatmentApproaches": [
                {
                    "id": 4738,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "EGFR amp"
                },
                {
                    "id": 2548,
                    "name": "EGFR Inhibitor (Pan)",
                    "profileName": "EGFR amp"
                },
                {
                    "id": 2549,
                    "name": "EGFR Antibody",
                    "profileName": "EGFR amp"
                }
            ]
        },
        {
            "id": 4004,
            "profileName": "EGFR amp PDGFRA amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 12767,
            "profileName": "EGFR S492R EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 12768,
            "profileName": "BRAF V600E EGFR S492R EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17304,
            "profileName": "EGFR amp MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22032,
            "profileName": "EGFR amp ERBB2 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22034,
            "profileName": "EGFR amp ERBB2 amp ERBB3 R103G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22287,
            "profileName": "EGFR act mut EGFR amp PTEN R308C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22289,
            "profileName": "EGFR G719A EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22292,
            "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24031,
            "profileName": "EGFR E746_A750del EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24170,
            "profileName": "EGFR act mut EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24172,
            "profileName": "EGFR act mut EGFR amp EGFR wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25921,
            "profileName": "BRAF V600E EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26141,
            "profileName": "EGFR amp PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27254,
            "profileName": "EGFR amp PTK2B dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27922,
            "profileName": "EGFR amp FGFR1 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27923,
            "profileName": "EGFR amp FGFR1 amp KRAS G13C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28960,
            "profileName": "EGFR amp ERBB2 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28988,
            "profileName": "EGFR amp EGFR over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28997,
            "profileName": "EGFR amp ERBB2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29854,
            "profileName": "EGFR G696_P1033dup EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30339,
            "profileName": "EML4 - ALK EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31072,
            "profileName": "EGFR amp KRAS amp MET del exon14",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31154,
            "profileName": "EGFR E746_A750del EGFR T790M EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31243,
            "profileName": "EGFR T790M EGFR act mut EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31573,
            "profileName": "BRAF V600E CDK6 amp EGFR amp KRAS Q61K MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31753,
            "profileName": "EGFR amp ERBB2 amp MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32952,
            "profileName": "EGFR T790M EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33828,
            "profileName": "EGFR I744_K745delinsKIPVAI EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35122,
            "profileName": "EGFR amp MET D1010H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35131,
            "profileName": "EGFR amp ERBB3 amp MET D1010H MET D1228N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 36194,
            "profileName": "EGFR exon 19 del EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}